Insilico Medicine news
Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced its nomination of a novel preclinical candidate (PCC) targeting 3C-like (3CL) protease for the treatment of COVID-19.
Insilico`s PCC is an orally available 3CL protease inhibitor with a novel structure generated using Insilico`s AI platform. The compound can be efficiently prepared with a two-step synthesis from commercial starting materials. I
Insilico Medicine ("Insilico"), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company has nominated a preclinical candidate (PCC) targeting methionine adenosyltransferase 2A (MAT2A) from AI-designed molecules for the treatment of methylthioadenosine phosphorylase (MTAP)-deleted cancers. The PCC is part of Insilico`s growing portfolio of synthetic lethality assets in development.
MTAP deletion is one of the most common
Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the first healthy volunteer has been dosed in a first-in-human microdose trial of ISM001-055.
ISM001-055 is a potentially first-in-class small molecule inhibitor of a novel biological target discovered by Pharma.AI, Insilico Medicine`s end-to-end AI-powered drug discovery platform.
Thursday, October 15, 2020 (9 am ET) - Insilico Medicine announced today that Taisho Pharmaceutical Co., Ltd. and Insilico have entered into a research collaboration to identify novel therapeutics against aging. Insilico Medicine will utilize both the target discovery and generative chemistry parts of its Pharma.AI platform in this collaboration. It will use its proprietary
Insilico Medicine is pleased to announce that it has entered into a research collaboration with Boehringer Ingelheim to utilize Insilico`s generative machine learning technology and proprietary Pandomics Discovery Platform with the aim of identifying potential therapeutic targets implicated in a variety of diseases.
"Insilico Medicine is very impressed with the Research Beyond Borders gro
Beijing Tide Pharmaceutical Co., Ltd. (Tide), a subsidiary of Sino Biopharmaceutical Limited, and Insilico Medicine, an artificial intelligence company developing end-to-end drug discovery pipelines, announced today that they are entering a collaboration, applying artificial intelligence (AI) technology to drug discovery, to jointly accelerate the process for multiple types of cancer treatment. This agreement includes an upfront payment, milestone payments, and royalties bas
Insilico Medicine is pleased to announce that it has entered into a research collaboration with Pfizer Inc. (NYSE: PFE) to utilize Insilico`s machine learning technology and proprietary Pandomics Discovery Platform with the aim of identifying real-world evidence for potential therapeutic targets implicated in a variety of diseases.
"Insilico is advancing its latest target identification systems utilizing machine le